2024
Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individuals
2021
Author Reply to Comment on “Assessment of Plasma Oxalate Concentration in Patients With CKD” by Oka et al.
Pfau A, Wytopil M, Chauhan K, Reichel M, Coca S, Aronson PS, Eckardt KU, Knauf F. Author Reply to Comment on “Assessment of Plasma Oxalate Concentration in Patients With CKD” by Oka et al. Kidney International Reports 2021, 6: 1194-1195. PMID: 33912771, PMCID: PMC8071653, DOI: 10.1016/j.ekir.2021.02.027.Peer-Reviewed Original ResearchPlasma oxalate concentration
2020
Assessment of Plasma Oxalate Concentration in Patients With CKD
Pfau A, Wytopil M, Chauhan K, Reichel M, Coca SG, Aronson PS, Eckardt KU, Knauf F. Assessment of Plasma Oxalate Concentration in Patients With CKD. Kidney International Reports 2020, 5: 2013-2020. PMID: 33163722, PMCID: PMC7609998, DOI: 10.1016/j.ekir.2020.08.029.Peer-Reviewed Original ResearchChronic kidney diseasePlasma oxalate concentrationGerman Chronic Kidney Disease (GCKD) studyChronic Kidney Disease studyObservational cohort studyGlomerular filtration rateLarge patient cohortKidney Disease studyKidney stone diseaseCKD progressionMedian eGFROngoing multicenterCohort studyKidney diseasePatient cohortPresent studyFiltration rateClinical trialsStone diseaseLarge cohortOxalate homeostasisPatientsDisease StudyPlasma samplesMaintenance of samplesEnteric Oxalate Secretion Mediated by Slc26a6 Defends against Hyperoxalemia in Murine Models of Chronic Kidney Disease
Neumeier LI, Thomson RB, Reichel M, Eckardt KU, Aronson PS, Knauf F. Enteric Oxalate Secretion Mediated by Slc26a6 Defends against Hyperoxalemia in Murine Models of Chronic Kidney Disease. Journal Of The American Society Of Nephrology 2020, 31: 1987-1995. PMID: 32660969, PMCID: PMC7461683, DOI: 10.1681/asn.2020010105.Peer-Reviewed Original ResearchConceptsEnteric oxalate secretionPlasma oxalate concentrationOxalate secretionModel of CKDChronic kidney diseaseIntestine of miceWild-type miceHealthy kidney functionOxalate clearanceWestern blot analysisKidney injuryKidney functionOxalate excretionWeekly injectionsKidney diseaseCKD modelExtrarenal clearanceOxalate transporter SLC26A6CKDMurine modelSignificant elevationOxalate homeostasisTransporter expressionMiceProtein expression
2017
Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease
Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney International Reports 2017, 2: 1050-1058. PMID: 29270514, PMCID: PMC5733827, DOI: 10.1016/j.ekir.2017.06.002.Peer-Reviewed Original ResearchEnd-stage renal diseasePlasma oxalate concentrationRenal diseaseCalcium oxalate supersaturationPlasma of patientsTraditional therapeutic regimensExtended treatment timeTherapeutic regimensExtended hemodialysisUremic toxin removalHemodialysisTherapeutic strategiesTreatment sessionsPatientsBaseline pDialysis equipmentHemodialfiltrationWeeksTreatment timeOxalate concentrationRespective treatmentsDiseasePrevious reportsTreatment modeHours
2007
Role of Anion Transporter SLC26A6 (CFEX) in Prevention of Hyperoxaluria and Urolithiasis
Aronson P. Role of Anion Transporter SLC26A6 (CFEX) in Prevention of Hyperoxaluria and Urolithiasis. AIP Conference Proceedings 2007, 900: 141-148. DOI: 10.1063/1.2723570.Commentaries, Editorials and LettersProximal tubulesNull miceOxalate secretionPlasma oxalate concentrationIntestinal oxalate secretionCalcium oxalate urolithiasisFormate exchangeOxalate exchangePrevention of hyperoxaluriaHigh incidenceOxalate urolithiasisHyperoxaluriaCFEXApical membraneRenal brush border vesiclesNet absorptionMiceBrush border vesiclesTubulesUrolithiasisSecretionXenopus oocytesAnion transportersFunctional expression
2006
Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6
Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nature Genetics 2006, 38: 474-478. PMID: 16532010, DOI: 10.1038/ng1762.Peer-Reviewed Original ResearchConceptsCalcium oxalate urolithiasisOxalate urolithiasisPlasma oxalate concentrationIntestinal oxalate secretionUrinary oxalate concentrationCommon urologic diseaseNet intestinal absorptionAnion exchanger SLC26A6Dietary oxalate restrictionSlc26a6-null miceSignificant hyperoxaluriaOxalate restrictionUrologic diseasesHigh incidenceIntestinal absorptionExchanger SLC26A6Mutant miceUrolithiasisMiceMajor constitutive roleNet absorptionOxalate secretionHyperoxaluriaOxalate concentrationEpithelial tissues